Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) were down 17.1% on Thursday . The stock traded as low as C$0.28 and last traded at C$0.32. Approximately 684,632 shares were traded during mid-day trading, an increase of 2% from the average daily volume of 673,865 shares. The stock had previously closed at C$0.38.
Hemostemix Stock Performance
The business’s fifty day simple moving average is C$0.15 and its 200-day simple moving average is C$0.10. The firm has a market capitalization of C$27.01 million, a PE ratio of -15.50 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Further Reading
- Five stocks we like better than Hemostemix
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Beyond Self-Driving Cars: Factory Automation Takes Center Stage
- How to Calculate Inflation Rate
- MarketBeat Week in Review – 01/27 – 01/31
- Growth Stocks: What They Are, Examples and How to Invest
- Trump 2.0: This Sector May See A Big Performance Boost
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
